Lv3
300 积分 2023-12-29 加入
A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy
15小时前
求助中
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy
16小时前
已完结
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
17小时前
已完结
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
17小时前
已完结
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial
18小时前
已完结
Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy
2天前
已完结
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
2天前
已完结
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
7个月前
已完结
Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism
7个月前
已完结
The peroxisome: an up-and-coming organelle in immunometabolism
7个月前
已完结
皖公网安备34019202002308
